Any feedback?
Information on EC 2.3.1.67 - 1-alkylglycerophosphocholine O-acetyltransferase and Organism(s) Homo sapiens
for references in articles please use BRENDA:EC2.3.1.67Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.3.1.67 1-alkylglycerophosphocholine O-acetyltransferaseSpecify your search results
Word Map
- 2.3.1.67
- paf-ah
-
acetylhydrolase
- paf-cpt
-
cholinephosphotransferase
- 1-o-alkyl-2-acetyl-sn-glycero-3-phosphocholine
- paf-acetylhydrolase
-
coa-independent
-
transacylase
-
dtt-insensitive
-
3hacetate
-
paf-synthesizing
- 1-o-alkyl-sn-glycero-3-phosphocholine
-
14carachidonic
-
phospholipase-a2
- medicine
- lppla2
- analysis
- drug development
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Reaction Schemes
Synonyms
lyso-paf-at, acetyl-coa:lyso-paf acetyltransferase, lyso-paf at, lyso-paf:acetyl-coa acetyltransferase, lyso-paf-acetyltransferase, acetyl-coa lyso-paf acetyltransferase, lyso-paf-act, lyso-pafat, lysopafat, lysopaf-at, 
more
topSYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
1-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase
-
-
-
-
acetyl-CoA:1-alkyl-2-lyso-sn-glycero-3-phosphocholine 2-O-acetyltransferase
-
-
-
-
acetyl-CoA:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase
-
acetyl-CoA:lyso-PAF acetyltransferase
acetyl-CoA:lysoPAF acetyltransferase
acetyltransferase, 1-alkyl-2-lysolecithin
-
-
-
-
acetyltransferase, 1-alkylglycerophosphocholine
-
-
-
-
acyl-CoA:1-alkyl-sn-glycero-3-phosphocholine acyltransferase
-
-
-
-
blood platelet-activating factor acetyltransferase
-
-
-
-
lyso-GPC:acetyl CoA acetyltransferase
-
-
-
-
lyso-PAF AT
lyso-platelet activating factor:acetyl-CoA acetyltransferase
-
-
-
-
lyso-platelet-activating factor acetyltransferase
lyso-platelet-activating factor:acetyl-CoA acetyltransferase
-
-
-
-
lysoPAF:acetyl CoA acetyltransferase
-
-
-
-
PAF acetyltransferase
-
-
-
-
platelet-activating factor acylhydrolase
-
-
-
-
platelet-activating factor-synthesizing enzyme
-
-
-
-
acetyl-CoA:lyso-PAF acetyltransferase
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Acyl group transfer
Acyl group transfer
-
-
-
-
PATHWAY SOURCE
PATHWAYS
SYSTEMATIC NAME
IUBMB Comments
acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine 2-O-acetyltransferase
-
CAS REGISTRY NUMBER
COMMENTARY
76773-96-1
-
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
-
lyso-PAF, lyso-platelet-activating factor
PAF, platelet-activating factor
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
acetyl-CoA + 1-hexadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
-
40% higher activity respect to the C18 analogue
-
?
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-6-phosphocholine
-
final step in remodelling pathway of PAF biosynthesis
-
?
acetyl-CoA + 1-octadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + acyl-lyso-glycero-3-phosphocholine
CoA + acetyl-acyl-glycero-3-phosphocholine
-
-
-
-
?
acetyl-CoA + alk-1-enyl-lyso-glycero-3-phosphoethanolamine
CoA + acetyl-alk-1-enyl-glycero-3-phosphoethanolamine
-
-
-
?
acetyl-CoA + alkyl-lyso-glycero-3-phosphoethanolamine
CoA + 2-acetyl-alkyl-glycero-3-phosphoethanolamine
-
-
-
?
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
alkyl-lyso-sn-glycero-3-phosphocholine is preferred to its saturated counterpart as substrate
-
?
acetyl-CoA + hexadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + lyso-phosphatidylcholine
CoA + 2-acetyl-1-acylphosphatidylcholine
-
-
-
?
acetyl-CoA + lyso-phosphatidylethanolamine
CoA + 2-acetyl-1-acyl-phosphatidylethanolamine
-
-
-
?
acetyl-CoA + lyso-platelet activating factor
CoA + platelet activating factor
-
-
-
-
?
acetyl-CoA + octadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
-
-
-
?
propionyl-CoA + alkyl-lyso-glycero-phosphocholine
CoA + 2-propionyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
additional information
?
-
enzyme is induced by bacterial endotoxin. The enzyme catalyzes not only biosynthesis of PAF from lyso-PAF but also incorporation of arachidonoyl-CoA to produce PAF precursor membrane glycerophospholipids (lysophosphatidylcholine acyltransferase activity). Under resting conditions, the enzyme prefers arachidonoyl-CoA and contributes to membrane biogenesis. Upon acute inflammatory stimulation with lipopolysaccharide, the activated enzyme utilizes acetyl-CoA more efficiently and produces PAF
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
substrates are d31-16:0 LPC or d4-lyso-PAF
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
-
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
intracellular redox state involved in regulating synthesis of platelet-activating factor (PAF)
-
-
?
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
-
lyso-PAF, lyso-platelet-activating factor
PAF, platelet-activating factor
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-6-phosphocholine
-
final step in remodelling pathway of PAF biosynthesis
-
?
acetyl-CoA + lyso-platelet activating factor
CoA + platelet activating factor
-
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
-
-
-
?
additional information
?
-
enzyme is induced by bacterial endotoxin. The enzyme catalyzes not only biosynthesis of PAF from lyso-PAF but also incorporation of arachidonoyl-CoA to produce PAF precursor membrane glycerophospholipids (lysophosphatidylcholine acyltransferase activity). Under resting conditions, the enzyme prefers arachidonoyl-CoA and contributes to membrane biogenesis. Upon acute inflammatory stimulation with lipopolysaccharide, the activated enzyme utilizes acetyl-CoA more efficiently and produces PAF
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
-
-
-
?
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine
-
irreversible inhibition dependent of both 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and enzyme concentration
1-O-alkyl-sn-glycero-3-phosphocholine
-
inhibition at high concentrations due to its detergent effect
3-chloro-1-(3-chloro-4-methoxyphenyl)-4-(2-methoxyphenoxy)-1H-pyrrole-2,5-dione
-
3-chloro-1-(4,5-dichloro-2-methoxyphenyl)-4-(2-hydroxyanilino)-1H-pyrrole-2,5-dione
-
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
i.e. Trolox, reduces production of platelet-activating factor (PAF) in H2O2-treated HUVEC cells
butyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
80.4% inhibition at 0.02 mM
lopinavir-r
-
remaining activity in human mesangial cells: 76%. By contrast no effect on activity is observed in blood of naiive patients treated with the drug
lysophosphatidylcholine
-
inhibition at high concentrations due to its detergent effect
methyl 4-[3-chloro-2,5-dioxo-4-(4-sulfamoylanilino)-2,5-dihydro-1H-pyrrol-1-yl]benzoate
-
N-acetylcysteine
reduces production of platelet-activating factor (PAF) in H2O2-treated HUVEC cells
propan-2-yl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
95.2% inhibition at 0.02 mM
propan-2-yl 4-(3-chloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
competitively inhibits the lyso-PAFAT activity with acetyl-CoA
propan-2-yl 4-[3-chloro-4-(2-hydroxyanilino)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
83.1% inhibition at 0.02 mM
propan-2-yl 4-[3-chloro-4-(morpholin-4-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
-
propyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
85.4% inhibition at 0.02 mM
pyrrolidinecarbodithioic acid
i.e. PDTC, reduces production of platelet-activating factor (PAF) in H2O2-treated HUVEC cells
resveratrol
-
0.157 microM, results in 50% inhibition in interleukin 1beta effect on catalytic activity
tenofovir-DF
-
remaining activity in human mesangial cells: 32%. By contrast no effect on activity is observed in blood of naiive patients treated with the drug
tyrosol
-
0.048 microM, results in 50% inhibition in interleukin 1beta effect on catalytic activity
additional information
500 ml/day of low-fat milk fortified with phytosterols, linoleic and alpha linolenic acids, vitamin C, vitamin E, vitamin A, vitamin B6, vitamin B12, folic acid, magnesium and selenium has no effect on the enzyme activity in vivo
-
additional information
identification of LPCAT2-specific inhibitors in order to ameliorate platelet-activating factor-related inflammatory diseases: N-phenylmaleimide derivatives are selected from a 174000-compound library using fluorescence-based high-throughput screening followed by the evaluation of the effects on LPCAT1 and LPCAT2 activities, cell viability, and cellular platelet-activating factor production. The selected compounds have low inhibitory effects on enzyme LPCAT1 activity which is mostly expressed in the lungs where it produces platelet-activating factor, indicating that adverse effects on respiratory functions may be avoided. Structure-activity relationship, overview
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
bovine serum albumin
-
optimal concentration of 1-1.5 mg/ml at short incubation periods and 2-2.5 mg bovine serum albumin/ml during longer incubation periods
-
H2O2
increased in concentration-dependent manner, fast but transitory activation, concentrations of H2O2 ranging from 1 to 10 mM, maximal effect at 10 mM, maximum reached within 20 min
interleukin 1beta
-
2.5 ng/ml, induces 2fold increase in intracellular platelet activating factor levels against non-stimulated cells, as well as in the specific activity of acetyl-CoA:lyso-PAF acetyltransferase at 3 h. Effect is inhibited in presence of tyrosol or resveratrol
-
N-formyl-methionyl-leucyl-phenylalanine
-
stimulation is dependent on the preincubation of cells with cytochalasin B, addition of tumor necrosis factor increases 50% alkyl-2-acetyl-sn-glycero-3-phosphocholine production
additional information
-
membrane-permeable oxidants more effective to provoke synthesis of platelet-activating factor (PAF), no effect on synthesis of platelet-activating factor (PAF) observed in cells treated with 10 mM 2,2'-azobis(2-amidinopropane) dihydrochloride or with 5 mM hydrophobic cumen hydroperoxide
-
additional information
membrane-permeable oxidants more effective to provoke synthesis of platelet-activating factor (PAF), no effect on synthesis of platelet-activating factor (PAF) observed in cells treated with 10 mM 2,2'-azobis(2-amidinopropane) dihydrochloride or with 5 mM hydrophobic cumen hydroperoxide
-
additional information
500 ml/day of low-fat milk fortified with phytosterols, linoleic and alpha linolenic acids, vitamin C, vitamin E, vitamin A, vitamin B6, vitamin B12, folic acid, magnesium and selenium has no effect on the enzyme activity in vivo
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00921
lyso-platelet-activating factor
-
total membrane fractions of mesangial cells
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0171
3,4-dichloro-1-(4,5-dichloro-2-methoxyphenyl)-1H-pyrrole-2,5-dione
Homo sapiens
pH 7.4, 37°C
0.00758
3-chloro-1-(3-chloro-4-methoxyphenyl)-4-(2-methoxyphenoxy)-1H-pyrrole-2,5-dione
Homo sapiens
pH 7.4, 37°C
0.02
3-chloro-1-(4,5-dichloro-2-methoxyphenyl)-4-(2-hydroxyanilino)-1H-pyrrole-2,5-dione
Homo sapiens
pH 7.4, 37°C
0.00116
3-chloro-4-(morpholin-4-yl)-1-(4-phenoxyphenyl)-1H-pyrrole-2,5-dione
Homo sapiens
pH 7.4, 37°C
0.00033
butyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
pH 7.4, 37°C
0.0116
methyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
pH 7.4, 37°C
0.02
methyl 4-[3-chloro-2,5-dioxo-4-(4-sulfamoylanilino)-2,5-dihydro-1H-pyrrol-1-yl]benzoate
Homo sapiens
pH 7.4, 37°C
0.00127
propan-2-yl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
pH 7.4, 37°C
0.00047
propan-2-yl 4-(3-chloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
pH 7.4, 37°C
0.0133
propan-2-yl 4-[3-chloro-4-(2-hydroxyanilino)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
Homo sapiens
pH 7.4, 37°C
0.02
propan-2-yl 4-[3-chloro-4-(morpholin-4-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
Homo sapiens
pH 7.4, 37°C
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
0.0000041
-
median activity of lyso-PAF-acetyltransferase in leukocyte homogenates of patients with heart failure
additional information
additional information
-
influence of phospholipids on specific activity at 37°C
additional information
-
exogenous addition of lyso-platelet-activating factor (PAF) without effect on acetyltransferase activity, block of enzyme activity by a tyrosine kinase inhibitor and a calmodulin antagonist in H2O2-stimulated cells suggests involvement of tyrosine kinase and calcium/calmodulin-dependent protein kinase in regulation of enzyme activity
additional information
exogenous addition of lyso-platelet-activating factor (PAF) without effect on acetyltransferase activity, block of enzyme activity by a tyrosine kinase inhibitor and a calmodulin antagonist in H2O2-stimulated cells suggests involvement of tyrosine kinase and calcium/calmodulin-dependent protein kinase in regulation of enzyme activity
additional information
-
specific activity of 32.4%, 1.7 ng/microl Tenofovir-DF in the cell incubation medium of HMC
additional information
-
specific activity of 76.2%, 1.9 ng/microl Lopinavir-r in the cell incubation medium of HMC
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
6.9
7.4
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
6 - 9
-
pH 6.0: about 80% of maximal activity, pH 9.0: about 70% of maximal activity
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
37
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
microsomal protein with three putative membrane-spanning domains
-
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
evolution
two entities of lyso-PAFAT belonging to the 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT) family: a constitutively expressed lyso-PAFAT, LPCAT1,and an inducible lyso-PAFAT, LPCAT2. LPCAT1 is mainly expressed in the lungs and produces PAF and dipalmitoyl-phosphatidylcholine, which is a main component of a pulmonary surfactant essential for respiration. LPCAT2 is mainly expressed in inflammatory cells and also possesses biosynthetic activities for PAF and cellular membrane phosphatidylcholine
metabolism
following extracellular stimulation, platelet-activating factor is rapidly biosynthesized via a remodeling pathway in inflammatory cells such as macrophages and neutrophils. In the remodeling pathway, one of the membrane phospholipids, 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine is hydrolyzed by phospholipase A2 to produce free fatty acids and lyso-PAF (1-O-alkyl-2-hydroxy-sn-glycero-3-phosphocholine). Acetyl-CoA:lyso-PAF acetyltransferase (lyso-PAFAT) subsequently converts lyso-PAF to PAF, which is rapidly degraded to lyso-PAF and acetic acid by PAF acetylhydrolases, terminating its effects
physiological function
physiological function
a key metabolic enzyme of platelet-activating factor (PAF) syntesis, a potent inflammatory lipid mediator. Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid implicated in physiological as well as pathological inflammatory processes such as atherogenesis. It affects several critical points of atherogenesis including thrombosis, inflammation and oxidation. Common risk factors for atherosclerosis, namely diabetes, cigarette smoking, oxidised low-density lipoprotein (LDL) and systemic inflammation, share elevated PAF and PAF-like lipids as a common feature
physiological function
platelet-activating factor (PAF) is a potent pro-inflammatory phospholipid mediator. In response to extracellular stimuli, PAF is rapidly biosynthesized by lyso-PAF acetyltransferase. Under inflammatory conditions, LPCAT2, but not LPCAT1, is activated and upregulated to produce the platelet-activating factor
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). LPCT4_HUMAN
524
1
57219
Swiss-Prot
other Location (Reliability: 5)
PCAT1_HUMAN
534
1
59151
Swiss-Prot
Mitochondrion (Reliability: 2)
PCAT2_HUMAN
544
1
60208
Swiss-Prot
other Location (Reliability: 3)
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
37
-
85% loss of activity after 2 h, 35% loss of activity after 2 h in the presence of DTT and 1-alkyl-2-lyso-sn-glycero-3-phosphate, microsomal preparation
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
1-alkyl-sn-glycero-3-phosphocholine at low concentration and lysophosphatidylcholine stabilizes microsomal preparation
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
gene LPCAT2, recombinant expression of FLAG-tagged human LPCAT2 in CHO cells
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
lysoPAF-AT shows a significant activation after 1-h infection with a maximum activity at 2-h infection with Salmonella enteritidis
-
under inflammatory conditions, LPCAT2, but not LPCAT1, is activated and upregulated to produce the platelet-activating factor
wine extracts (Robola and Cabernet Sauvignon) inhibit the enzyme activity 6 h after meal consumption
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
analysis
procedure for identification of LPCAT2-specific inhibitors via high-throughput screening
drug development
identification of LPCAT2-specific inhibitors in order to ameliorate PAF-related inflammatory diseases, fluorescence-based high-throughput library screening
medicine
medicine
-
the results increases the understanding of the clinical implications of platelet-activating factor inhibition with regard to HIV infection
medicine
-
study on the impact of diet on platelet-activating factor metabolism. Platelet-activating factor is inversely correlated with antioxidant-rich foods (herbal drinks and coffee), the dietary antioxidant capacity as well as a dietary pattern characterized by legumes, vegetables, poultry and fish. Platelet-activating factor is positively correlated to percentage of fat intake. Lyso-PAF acetyltransferase is also negatively associated with healthy patterns (fruits, nuts and herbal drinks, and a pattern rich in olive oil and whole-wheat products), as well as the dietary antioxidant capacity and percentage of monounsaturated fatty acids
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Lee, T.C.; Vallari, D.S.; Snyder, F.
1-Alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase
Methods Enzymol.
209
396-401
1992
Homo sapiens
Ninio, E.; Joly, F.; Bessou, G.
Biosynthesis of paf-acether. XI. Regulation of acetyltransferase by enzyme-substrate imbalance
Biochim. Biophys. Acta
963
288-294
1988
Homo sapiens
Yamazaki, R.; Sugatani, J.; Fujii, I.; Kuroyanagi, M.; Umehara, K.; Ueno, A.; Suzuki, Y.; Miwa, M.
Development of a novel method for determination of acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine acetyltransferase activity and its application to screening for acetyltransferase inhibitors. Inhibition by magnolol and honokiol from Magnoliae cortex
Biochem. Pharmacol.
47
995-1006
1994
Homo sapiens, Rattus norvegicus
Garcia, C.; Montero, M.; Alvarez, J.; Sanchez Crespo, M.
Biosynthesis of platelet-activating factor (PAF) induced by chemotactic peptide is modulated at the lyso-PAF:acetyl-CoA acetyltransferase level by calcium transient and phosphatidic acid
J. Biol. Chem.
268
4001-4008
1993
Homo sapiens
Nomikos, T.N.; Iatrou, C.; Demopoulos, C.A.
Acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase (lyso-PAF AT) activity in cortical and medullary human renal tissue
Eur. J. Biochem.
270
2992-3000
2003
Homo sapiens
Owen, J.S.; Baker, P.R.; OFlaherty, J.T.; Thomas, M.J.; Samuel, M.P.; Wooten, R.E.; Wykle, R.L.
Stress-induced platelet-activating factor synthesis in human neutrophils
Biochim. Biophys. Acta
1733
120-129
2005
Homo sapiens
Tosaki, T.; Sakamoto, H.; Kitahara, J.; Imai, H.; Nakagawa, Y.
Enhancement of acetyl-CoA: 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase activity by hydrogen peroxide
Biol. Pharm. Bull.
30
272-278
2007
Homo sapiens, Homo sapiens (Q7L5N7)
Shindou, H.; Hishikawa, D.; Nakanishi, H.; Harayama, T.; Ishii, S.; Taguchi, R.; Shimizu, T.
A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells: cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase
J. Biol. Chem.
282
6532-6539
2007
Homo sapiens (Q7L5N7), Mus musculus (Q8BYI6)
Fragopoulou, E.; Iatrou, C.; Demopoulos, C.A.
Characterization of acetyl-CoA:lyso-PAF acetyltransferase of human mesangial cells
Mediators Inflamm.
2005
263-272
2005
Homo sapiens
Tsoupras, A.B.; Chini, M.; Tsogas, N.; Fragopoulou, E.; Nomikos, T.; Lioni, A.; Mangafas, N.; Demopoulos, C.A.; Antonopoulou, S.; Lazanas, M.C.
Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?
AIDS Res. Hum. Retroviruses
24
1079-1086
2008
Homo sapiens
Egea, L.; Gimenez, R.; Lucia, D.; Modolell, I.; Badia, J.; Baldoma, L.; Aguilar, J.
Increased production of the ether-lipid platelet-activating factor in intestinal epithelial cells infected by Salmonella enteritidis
Biochim. Biophys. Acta
1781
270-276
2008
Homo sapiens
Detopoulou, P.; Nomikos, T.; Fragopoulou, E.; Antonopoulou, S.; Kotroyiannis, I.; Vassiliadou, C.; Panagiotakos, D.B.; Chrysohoou, C.; Pitsavos, C.; Stefanadis, C.
Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure
Clin. Biochem.
42
44-49
2009
Homo sapiens
Ntzouvani, A.; Nomikos, T.; Petrogianni, M.; Dede, V.; Stamatakis, G.; Manios, Y.
Effect of fortified milk on lyso-platelet-activating factor acetyltranferase and lipoprotein-associated phospholipase A2 in hypercholesterolemic adults
Eur. J. Lipid Sci. Technol.
115
142-152
2013
Homo sapiens (Q7L5N7)
-
Detopoulou, P.; Fragopoulou, E.; Nomikos, T.; Yannakoulia, M.; Stamatakis, G.; Panagiotakos, D.B.; Antonopoulou, S.
The relation of diet with PAF and its metabolic enzymes in healthy volunteers
Eur. J. Nutr.
54
25-34
2015
Homo sapiens
Tarui, M.; Shindou, H.; Kumagai, K.; Morimoto, R.; Harayama, T.; Hashidate, T.; Kojima, H.; Okabe, T.; Nagano, T.; Nagase, T.; Shimizu, T.
Selective inhibitors of a PAF biosynthetic enzyme lysophosphatidylcholine acyltransferase 2
J. Lipid Res.
55
1386-1396
2014
Homo sapiens (Q7L5N7), Mus musculus (Q8BYI6), Mus musculus
Vlachogianni, I.C.; Fragopoulou, E.; Stamatakis, G.M.; Kostakis, I.K.; Antonopoulou, S.
Platelet activating factor (PAF) biosynthesis is inhibited by phenolic compounds in U-937 cells under inflammatory conditions
Prostaglandins Other Lipid Mediat.
121
176-183
2015
Homo sapiens
Gavriil, L.; Detopoulou, M.; Petsini, F.; Antonopoulou, S.; Fragopoulou, E.
Consumption of plant extract supplement reduces platelet activating factor-induced platelet aggregation and increases platelet activating factor catabolism a randomised, double-blind and placebo-controlled trial
Br. J. Nutr.
121
982-991
2019
Homo sapiens
EXTERNAL LINKS (specific for EC-Number 2.3.1.67)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
